Literature DB >> 1704000

Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe.

J Goudsmit1, R H Meloen, R Brasseur.   

Abstract

Antibodies of individuals infected with the human immunodeficiency virus type 1 (HIV-1) were used to probe the antigenicity of the HIV-1 transmembrane protein of 41 kD (gp41) by antibody-reactive peptide scanning (Pepscan). Eleven distinct sequential antibody-binding sites were defined by testing reactivity to 339 overlapping nonapeptides spanning the complete gp41 amino acid sequence. Such analysis only maps continuous antibody-binding sites of nine amino acids in length and does not identify putative discontinuous or assembled epitopes. Three B cell epitopes (aa 609-622; aa 655-699; aa 664-681) at the amino-terminal border of the putative transmembrane anchor and two (aa 732-748; aa 744-762) at the carboxyl-terminal border of this domain were the most antigenic. One antibody-binding domain (aa 834-852) with four amino acids homologous to the beta-1 domain of HLA class II beta-chain was recognized by the serum in 1 of 4 AIDS patients tested and not by any of the eight sera from symptom-free individuals. Although functional domains of gp41 involved in virus replication, cytopathicity and possibly immunosuppression were shown to bind antibodies of HIV-1-infected individuals, no relationship between antibody recognition patterns and disease progression was apparent.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1704000     DOI: 10.1159/000150169

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  13 in total

1.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  A vaccine for HIV type 1: the antibody perspective.

Authors:  D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

3.  What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

Authors:  Marina R Alexander; Rajesh Ringe; Rogier W Sanders; James E Voss; John P Moore; Per Johan Klasse
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

4.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.

Authors:  J Y Xu; M K Gorny; T Palker; S Karwowska; S Zolla-Pazner
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.

Authors:  M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.

Authors:  Henry E Neuman de Vegvar; Rama Rao Amara; Lawrence Steinman; Paul J Utz; Harriet L Robinson; William H Robinson
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 7.  The tale of the long tail: the cytoplasmic domain of HIV-1 gp41.

Authors:  Thomas S Postler; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

8.  The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific.

Authors:  M Urban; W Britt; M Mach
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.

Authors:  S Munir Alam; Richard M Scearce; Robert J Parks; Kelly Plonk; Steven G Plonk; Laura L Sutherland; Miroslaw K Gorny; Susan Zolla-Pazner; Stacie Vanleeuwen; M Anthony Moody; Shi-Mao Xia; David C Montefiori; Georgia D Tomaras; Kent J Weinhold; Salim Abdool Karim; Charles B Hicks; Hua-Xin Liao; James Robinson; George M Shaw; Barton F Haynes
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 10.  How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.

Authors:  P J Klasse
Journal:  Expert Rev Vaccines       Date:  2016-01-06       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.